A focused review published in Pharmacological Research (Nauman & Johnson, final edited form Dec 9, 2021; author manuscript in PMC) takes a close look at the purple mangosteen (Garcinia mangostana) and a class of plant chemicals called xanthones — especially the abundant compound α‑mangostin — to ask a simple question: do these molecules have real anticancer potential?
What the review covers
The paper is a scientific review of preclinical and limited human data. The authors summarize laboratory cell studies, animal experiments, preclinical pharmacokinetics, and a small number of human/product studies that have measured antioxidant activity and short‑term tolerability of mangosteen preparations. The focus is on xanthones isolated from the fruit and other plant parts; the review emphasizes mechanisms and areas where the evidence is strongest and where it falls short.
Key compounds
Mangosteen contains a rich assortment of polyphenolic xanthones — more than 70 have been isolated. α‑Mangostin is the most abundant and best studied. Other named xanthones discussed in the review include gartanin, β‑mangostin, γ‑mangostin, garcinone C and garcinone E.
What the laboratory and animal studies show
Across many in vitro cell experiments and multiple animal tumor models, α‑mangostin and related xanthones reduce cancer cell viability, trigger apoptosis (programmed cell death), limit colony formation and can slow tumor growth. Reported effects span numerous cancer types in preclinical work (for example: breast, colon, prostate, liver and glioblastoma models). The review also summarizes non‑cancer bioactivities seen in preclinical studies, including antioxidant, anti‑inflammatory and antimicrobial actions, and hints of metabolic and organ‑protective effects in animals.
How they might work
The review lays out several molecular pathways modulated by mangosteen xanthones in preclinical studies: PI3K/AKT, AMPK, MAPK signaling, STAT3, cyclin‑dependent kinases (CDKs), matrix metalloproteinases (MMPs) and reactive oxygen species (ROS) signaling. In plain terms, those effects can alter cell growth signals, inflammation and oxidative stress — mechanisms that help explain the laboratory observations of slower growth, more cell death and reduced invasion in model systems.
Pharmacokinetics and safety notes
Preclinical pharmacokinetic work in rodents shows that α‑mangostin is absorbed and primarily undergoes Phase II metabolism (notably glucuronidation), and measurable plasma levels have been reported in animal studies at biologically active doses. Small human product studies cited in the review report antioxidant effects and generally short‑term tolerability of some mangosteen preparations, but the review makes clear that human data are limited.
What this review does — and does not — establish
Established: substantial preclinical evidence supports antioxidant, anti‑inflammatory, antimicrobial and anticancer bioactivities of mangosteen xanthones and identifies plausible molecular targets for those actions. There are also some pharmacokinetic data from animals and limited human/product studies showing absorption and short‑term tolerability.
Not established: clinical efficacy for preventing or treating cancer (or other specific human diseases) is not demonstrated. The review emphasizes that clinical anticancer activity has not been shown and that large, well‑controlled human trials are lacking. It also notes the absence of validated dosing, standardized preparations (α‑mangostin content varies) and comprehensive long‑term safety data for concentrated supplements.
Practical takeaways for readers
– Eating fresh mangosteen provides polyphenolic xanthones and contributes to antioxidant intake, which aligns with general advice to include polyphenol‑rich fruits in the diet.
– The anticancer and many other reported benefits are supported mainly by laboratory and animal studies. These findings are promising but do not prove that mangosteen or xanthone supplements prevent or treat cancer in people.
– Commercial mangosteen juices and supplements have shown antioxidant activity in small studies and have been tolerated short term, but product composition varies and long‑term safety and effective clinical dosing are unknown. Be cautious of overstated health claims and consult a clinician before taking concentrated extracts, especially if you take other medications.
Bottom line
The purple mangosteen is a rich source of xanthones with a compelling body of preclinical data that explains why researchers are interested in α‑mangostin and related compounds as potential anticancer agents. That promise is real in the lab, but it remains a promise until robust clinical trials demonstrate safety and efficacy in people.
Reference: Nauman MC, Johnson JJ. The purple mangosteen (Garcinia mangostana): Defining the anticancer potential of selected xanthones. Pharmacol Res. 2021 Dec 9;175:106032. Author manuscript available in PMC.
Leave a Reply